Compare Stocks: DTIL, ANNX, VSTM, and NVCT

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANNX Annexon	$3.64 -4.2%	$4.87	$2.54 ▼ $7.18	$690.07M	1.21	2.79 million shs	3.50 million shs
DTIL Precision BioSciences	$6.22 -1.7%	$7.39	$3.53 ▼ $9.62	$171.68M	1.24	247,199 shs	203,968 shs
NVCT Nuvectis Pharma	$20.22 -6.5%	$21.67	$5.55 ▼ $29.27	$660.06M	-0.26	196,163 shs	191,807 shs
VSTM Verastem	$7.74 -0.8%	$7.02	$3.43 ▼ $10.82	$700.96M	0.32	2.39 million shs	1.06 million shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANNX Annexon	0.00%	-13.95%	-30.67%	-33.73%	+29.08%
DTIL Precision BioSciences	0.00%	-6.75%	-25.95%	-14.68%	+21.25%
NVCT Nuvectis Pharma	0.00%	-8.09%	-19.73%	-25.63%	+239.83%
VSTM Verastem	0.00%	+4.03%	+4.88%	+104.76%	-10.10%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANNX Annexon	$3.64 -4.2%	$4.87	$2.54 ▼ $7.18	$690.07M	1.21	2.79 million shs	3.50 million shs
DTIL Precision BioSciences	$6.22 -1.7%	$7.39	$3.53 ▼ $9.62	$171.68M	1.24	247,199 shs	203,968 shs
NVCT Nuvectis Pharma	$20.22 -6.5%	$21.67	$5.55 ▼ $29.27	$660.06M	-0.26	196,163 shs	191,807 shs
VSTM Verastem	$7.74 -0.8%	$7.02	$3.43 ▼ $10.82	$700.96M	0.32	2.39 million shs	1.06 million shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANNX Annexon	0.00%	-13.95%	-30.67%	-33.73%	+29.08%
DTIL Precision BioSciences	0.00%	-6.75%	-25.95%	-14.68%	+21.25%
NVCT Nuvectis Pharma	0.00%	-8.09%	-19.73%	-25.63%	+239.83%
VSTM Verastem	0.00%	+4.03%	+4.88%	+104.76%	-10.10%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANNX Annexon	2.40	Hold	$15.14	316.01% Upside
DTIL Precision BioSciences	2.60	Moderate Buy	$32.25	418.49% Upside
NVCT Nuvectis Pharma	2.80	Moderate Buy	$36.25	79.28% Upside
VSTM Verastem	2.82	Moderate Buy	$13.83	78.73% Upside

Current Analyst Ratings Breakdown

Latest DTIL, ANNX, VSTM, and NVCT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/24/2026	NVCT Nuvectis Pharma	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$39.00
9/21/2026	NVCT Nuvectis Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/17/2026	VSTM Verastem	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform
9/11/2026	VSTM Verastem	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$18.00
9/11/2026	VSTM Verastem	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$18.00
9/4/2026	NVCT Nuvectis Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/4/2026	VSTM Verastem	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/1/2026	NVCT Nuvectis Pharma	Loop Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$40.00
9/1/2026	ANNX Annexon	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$10.00 ➝ $14.00
9/1/2026	NVCT Nuvectis Pharma	Lucid Cap Mkts Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/24/2026	NVCT Nuvectis Pharma	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight

(Data available from 9/27/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANNX Annexon	N/A	N/A	N/A	N/A	$1.42 per share	N/A
DTIL Precision BioSciences	$45.06M	3.81	N/A	N/A	$4.03 per share	1.54
NVCT Nuvectis Pharma	N/A	N/A	N/A	N/A	$0.72 per share	N/A
VSTM Verastem	$87.53M	8.01	N/A	N/A	$0.74 per share	10.46

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANNX Annexon	-$206.69M	-$1.16	N/A	N/A	N/A	N/A	-106.15%	-79.82%	11/9/2026 (Estimated)
DTIL Precision BioSciences	-$45.72M	-$2.80	N/A	N/A	N/A	-96.73%	-72.52%	-32.25%	11/2/2026 (Estimated)
NVCT Nuvectis Pharma	-$26.44M	-$1.31	N/A	N/A	N/A	N/A	-184.25%	-105.24%	11/3/2026 (Estimated)
VSTM Verastem	-$209.47M	-$2.66	N/A	N/A	N/A	-231.59%	-467.49%	-94.54%	11/3/2026 (Estimated)

Latest DTIL, ANNX, VSTM, and NVCT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	ANNX Annexon	-$0.2388	-$0.28	-$0.0412	-$0.28	$6.50 million	N/A
8/6/2026	Q2 2026	DTIL Precision BioSciences	-$0.8040	-$1.26	-$0.4560	-$1.26	$0.74 million	N/A
8/6/2026	Q2 2026	VSTM Verastem	-$0.4305	-$0.35	+$0.0805	-$0.35	$22.88 million	$40.08 million
8/4/2026	Q2 2026	NVCT Nuvectis Pharma	-$0.2620	-$0.30	-$0.0380	-$0.30	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANNX Annexon	N/A	N/A	N/A	N/A	N/A
DTIL Precision BioSciences	N/A	N/A	N/A	N/A	N/A
NVCT Nuvectis Pharma	N/A	N/A	N/A	N/A	N/A
VSTM Verastem	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANNX Annexon	N/A	5.53	5.53
DTIL Precision BioSciences	0.50	12.82	12.82
NVCT Nuvectis Pharma	N/A	1.68	1.68
VSTM Verastem	1.48	2.25	2.22

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANNX Annexon	N/A
DTIL Precision BioSciences	37.99%
NVCT Nuvectis Pharma	96.77%
VSTM Verastem	88.37%

Insider Ownership

Company	Insider Ownership
ANNX Annexon	10.31%
DTIL Precision BioSciences	2.70%
NVCT Nuvectis Pharma	28.55%
VSTM Verastem	1.94%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANNX Annexon	92	189.58 million	170.03 million	Optionable
DTIL Precision BioSciences	67	27.60 million	26.86 million	No Data
NVCT Nuvectis Pharma	13	32.64 million	23.32 million	Not Optionable
VSTM Verastem	102	90.56 million	88.81 million	Optionable

DTIL, ANNX, VSTM, and NVCT Headlines

Recent News About These Companies

Financial Comparison: Nektar Therapeutics (NASDAQ:NKTR) and Verastem (NASDAQ:VSTM)

September 27 at 2:15 AM | americanbankingnews.com

Verastem (NASDAQ:VSTM) Raised to "Hold" at Wall Street Zen

September 27 at 1:07 AM | americanbankingnews.com

Verastem (NASDAQ:VSTM) Upgraded to Hold at Wall Street Zen

September 27 at 1:05 AM | marketbeat.com

Verastem data on ovarian cancer drug combo set for IGCS 2026

September 25 at 7:54 PM | streetinsider.com

Verastem Oncology Announces Late-Breaking Oral Presentation of RAMP 201 Low-Grade Serous Ovarian Cancer Molecular Profiling and Tumor Biomarker Analysis at IGCS 2026 Annual Global Meeting

September 24 at 9:00 AM | businesswire.com

Verastem (NASDAQ:VSTM) Shares Up 7.1% - Still a Buy?

September 22, 2026 | marketbeat.com

Verastem Highlights Ovarian Cancer Launch, KRAS G12D Program at H.C. Wainwright

September 21, 2026 | marketbeat.com

Verastem, Inc. (NASDAQ:VSTM) Given Average Recommendation of "Moderate Buy" by Analysts

September 21, 2026 | americanbankingnews.com

Verastem, Inc. (NASDAQ:VSTM) Given Consensus Recommendation of "Moderate Buy" by Brokerages

September 21, 2026 | marketbeat.com

Verastem's Shares Not Fully Valuing its Growth Potential, RBC Says

September 19, 2026 | finance.yahoo.com

Wolfe Research Begins Coverage on Verastem (NASDAQ:VSTM)

September 19, 2026 | americanbankingnews.com

Wall Street Zen Downgrades Verastem (NASDAQ:VSTM) to Sell

September 19, 2026 | americanbankingnews.com

Verastem (NASDAQ:VSTM) Downgraded by Wall Street Zen to "Sell"

September 19, 2026 | marketbeat.com

RBC Capital Keeps Their Buy Rating on Verastem (VSTM)

September 18, 2026 | theglobeandmail.com

Verastem (NASDAQ:VSTM) Coverage Initiated by Analysts at Wolfe Research

September 17, 2026 | marketbeat.com

H.C. Wainwright Reiterates Buy Rating on Verastem (VSTM)

September 14, 2026 | streetinsider.com

Bank of New York Mellon Corp Makes New Investment in Verastem, Inc. $VSTM

September 12, 2026 | marketbeat.com

Verastem's (VSTM) "Buy" Rating Reiterated at HC Wainwright

September 11, 2026 | marketbeat.com

Verastem: Avutometinib Plus Defactinib Data De-Risk Efficacy Thesis; Buy Rating Reiterated With Unchanged $18 Price Target

September 11, 2026 | tipranks.com

BTIG Research Reaffirms "Buy" Rating for Verastem (NASDAQ:VSTM)

September 11, 2026 | marketbeat.com

Opaleye Management Inc. Purchases New Position in Verastem, Inc. $VSTM

September 11, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

DTIL, ANNX, VSTM, and NVCT Company Descriptions

Annexon NASDAQ:ANNX

$3.64 -0.16 (-4.21%)

Closing price 09/25/2026 04:00 PM Eastern

Extended Trading

$3.86 +0.22 (+6.04%)

As of 09/25/2026 07:58 PM Eastern

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.

Precision BioSciences NASDAQ:DTIL

$6.22 -0.11 (-1.74%)

Closing price 09/25/2026 04:00 PM Eastern

Extended Trading

$6.22 +0.00 (+0.08%)

As of 09/25/2026 07:30 PM Eastern

Precision BioSciences, Inc., an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA. In addition, it develops PBGENE-NVS for sickle cell disease/beta thalassemia for insertion; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LL2 (insertion), a liver directed target; PBGENE-LL3, a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. The company has license and collaboration agreement with Caribou Biosciences, Inc.; license agreement with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; development and license agreement with Eli Lilly and Company for the research and development of potential in vivo therapies for genetic disorders; Cellectis S.A.; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; Duke University; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

Nuvectis Pharma NASDAQ:NVCT

$20.22 -1.41 (-6.52%)

Closing price 09/25/2026 04:00 PM Eastern

Extended Trading

$20.25 +0.03 (+0.15%)

As of 09/25/2026 07:47 PM Eastern

Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma. It is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trails that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.

Verastem NASDAQ:VSTM

$7.74 -0.06 (-0.77%)

Closing price 09/25/2026 04:00 PM Eastern

Extended Trading

$7.75 +0.01 (+0.18%)

As of 09/25/2026 07:48 PM Eastern

Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest DTIL, ANNX, VSTM, and NVCT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest DTIL, ANNX, VSTM, and NVCT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

DTIL, ANNX, VSTM, and NVCT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

DTIL, ANNX, VSTM, and NVCT Company Descriptions

Annexon NASDAQ:ANNX

Precision BioSciences NASDAQ:DTIL

Nuvectis Pharma NASDAQ:NVCT

Verastem NASDAQ:VSTM

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest DTIL, ANNX, VSTM, and NVCT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest DTIL, ANNX, VSTM, and NVCT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

DTIL, ANNX, VSTM, and NVCT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

DTIL, ANNX, VSTM, and NVCT Company Descriptions

Annexon NASDAQ:ANNX

Precision BioSciences NASDAQ:DTIL

Nuvectis Pharma NASDAQ:NVCT

Verastem NASDAQ:VSTM

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools